New combo therapy aims to shrink liver tumors before surgery and prevent return
NCT ID NCT07268131
First seen Jan 06, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tests a new approach for people with liver cancer that is too large or numerous for standard transplant criteria but can still be surgically removed. Participants will receive a liver-directed treatment (TACE) plus an immunotherapy drug (QL1706) before surgery, then continue the immunotherapy after surgery. The goal is to see if this combination can shrink tumors enough to improve surgery outcomes and reduce the chance of cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.